U.S. Environmental Protection Agency, National Exposure Research Laboratory, Ecosystems Research Division, Athens, GA 30605, USA.
Drug Metab Dispos. 2010 Dec;38(12):2232-8. doi: 10.1124/dmd.110.034819. Epub 2010 Aug 24.
The extent to which membrane-disrupting agents, such as alamethicin, may alter cofactor transport and influence in vitro kinetic measurements of glucuronidation is a major concern regarding the characterization and extrapolation of inter- and intraspecies pharmacokinetics of bisphenol A (BPA). An additional concern is the omission of a BPA intestinal metabolism component in current pharmacokinetic models used to assess oral exposure. In this study, BPA glucuronidation in native hepatic microsomes from female rat and female human liver displayed higher V(max) values than that in males. In the presence of alamethicin, all hepatic V(max) values increased; however, this increase was disproportionately greater in males and gender differences were no longer observed. Female rats exhibited a much higher K(m) than all other species and genders; the addition of alamethicin had little influence on K(m) values for any of the test systems. The dissimilar K(m) measured for female rat suggests that different UDP-glucuronosyltransferase (UGT) enzyme(s) are involved in BPA glucuronidation. The presence of different UGTs in female rat was confirmed using Hill coefficients measured from diclofenac-mediated chemical inhibition assays within hepatic microsomes and purified human UGT2B7 and UGT2B15. Mixed-gender human intestinal microsomes showed little BPA glucuronidation reactivity compared with those from male rat intestine. Male rat intestinal microsomes in the presence of alamethicin exhibited a V(max) that was nearly 30-fold higher than that for mixed human microsomes. The species and gender metabolic differences we observed between rat and human liver and intestine provide key information for delineating BPA pharmacokinetics needed for human health risk assessment.
膜破坏剂(如阿来霉素)可能改变辅助因子的转运,并影响体外葡萄糖醛酸化的动力学测量,这是关于双酚 A(BPA)的种间和种内药代动力学特征和外推的主要关注点。另一个关注点是,在目前用于评估口服暴露的药代动力学模型中,忽略了 BPA 的肠道代谢成分。在这项研究中,雌性大鼠和女性人肝原生肝微粒体中的 BPA 葡萄糖醛酸化显示出比雄性更高的 Vmax 值。在阿来霉素存在的情况下,所有肝 Vmax 值均增加;然而,这种增加在雄性中不成比例地更大,并且性别差异不再观察到。雌性大鼠表现出比所有其他物种和性别更高的 Km 值;阿来霉素的添加对任何测试系统的 Km 值几乎没有影响。雌性大鼠测量到的 Km 值不同表明,BPA 葡萄糖醛酸化涉及不同的 UDP-葡萄糖醛酸基转移酶(UGT)酶。使用在肝微粒体和纯化的人 UGT2B7 和 UGT2B15 中进行的双氯芬酸介导的化学抑制测定测量的 Hill 系数,证实了雌性大鼠中存在不同的 UGT。与雄性大鼠肠相比,混合性别人肠微粒体显示出很少的 BPA 葡萄糖醛酸化反应性。在阿来霉素存在下的雄性大鼠肠微粒体显示出的 Vmax 值比混合人微粒体高近 30 倍。我们在大鼠和人肝和肠之间观察到的种间和性别代谢差异,为进行人类健康风险评估所需的 BPA 药代动力学提供了关键信息。